Evidence map›Paper›PMID 22220837›Full record

ArticleJournal of the American Chemical Society2012

A role for a single-stranded junction in RNA binding and specificity by the Tetrahymena group I ribozyme.

Xuesong Shi, Sergey V Solomatin, Daniel Herschlag

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xuesong ShiDepartment of Biochemistry, Stanford University, Stanford, California 94305, USA.
Sergey V Solomatin
Daniel Herschlag
Stanford University · US

Funding

Enzymology of a Catalytic RNA MoleculeR37GM049243 · NIGMS · STANFORD UNIVERSITY · PI HERSCHLAG, DANIEL · 2002 to 2011
$4.2M
ENZYMOLOGY OF A CATALYTIC RNA MOLECULER01GM049243 · NIGMS · STANFORD UNIVERSITY · PI HERSCHLAG, DANIEL · 1993 to 2016
$2.3M
NIGMS NIH HHS GM49243NIGMS NIH HHS R01 GM049243NIGMS NIH HHS R37 GM049243
6 · The paper itself

Abstract

We have investigated the role of a single-stranded RNA junction, J1/2, that connects the substrate-containing P1 duplex to the remainder of the Tetrahymena group I ribozyme. Single-turnover kinetics, fluorescence anisotropy, and single-molecule fluorescence resonance energy transfer studies of a series of J1/2 mutants were used to probe the sequence dependence of the catalytic activity, the P1 dynamics, and the thermodynamics of docking of the P1 duplex into the ribozyme's catalytic core. We found that A29, the center A of three adenosine residues in J1/2, contributes 2 orders of magnitude to the overall ribozyme activity, and double-mutant cycles suggested that J1/2 stabilizes the docked state of P1 over the undocked state via a tertiary interaction involving A29 and the first base pair in helix P2 of the ribozyme, A31·U56. Comparative sequence analysis of this group I intron subclass suggests that the A29 interaction sets one end of a molecular ruler whose other end specifies the 5'-splice site and that this molecular ruler is conserved among a subclass of group I introns related to the Tetrahymena intron. Our results reveal substantial functional effects from a seemingly simple single-stranded RNA junction and suggest that junction sequences may evolve rapidly to provide important interactions in functional RNAs.

Indexed as

Binding SitesBiocatalysisRNARNA, CatalyticSubstrate SpecificityTetrahymenaThermodynamicsRNARNA, Catalytic

Identifiers

PMID22220837
PMCPMC3277301
OpenAlexW2002128365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.